Serving To Educate Primary Care Clinicians On Metabolic Issues
Home
Subscribe
Feedback
Contact Us
Evidence Based Medicine
Medical Education
Metabolic Diseases
About Us
PCMG CME
PCMG Non-CME
Resources
Needs Survey
Commentaries
Survey
NPACE Webinar Post
I am a(n)…
Select...
MD/DO
NP/RN
PA
Other
How many years have you been in practice?
Select...
1-5
6-10
11-15
16-20
Over 20
What is your practice setting?
Select...
Solo Practice
Group Practice
Hospital
Clinic
Academic
Other
Number of patients seen per month with T2DM
1-10
11-20
21-30
31-40
41-50
Over 50
Number of patients seen per month with CKD or DKD?
Select...
1-10
11-20
21-30
31-40
41-50
Over 50
Please rate the following:
Degree to which your educational expectations were met
Select...
Excellent
Above Average
Average
Fair
Poor
Relevance to your practice
Select...
Excellent
Above Average
Average
Fair
Poor
Effective faculty presenter
Select...
Excellent
Above Average
Average
Fair
Poor
Overall Presentation
Select...
Excellent
Above Average
Average
Fair
Poor
Please rate the degree to which the Learning Objectives were met.
Identify the risks of kidney disease and their consequences in patients with T2DM.
Select...
Completely
Mostly
Somewhat
Not at all
Appropriately screen for the presence of CKD in patients with T2DM.
Select...
Completely
Mostly
Somewhat
Not at all
Initiate evidence-based therapy to slow the progression of kidney disease in patients with T2DM and CKD.
Select...
Completely
Mostly
Somewhat
Not at all
Become familiar with the mineralocorticoid receptor antagonists and their role in the treatment of patients with DKD.
Select...
Completely
Mostly
Somewhat
Not at all
Agree or Disagree?
The presentation was fair and balanced, free of commercial bias.
Select...
YES
NO
I feel more competent as a result of the presentation.
Select...
YES
NO
The presentation was scientifically rigorous.
Select...
YES
NO
The content contributed valuable information that will assist in improving patient outcomes
Select...
Strongly Agree
Agree
Unsure
Disagree
Strongly Disagree
Will you change your practice behaviors as a result of the presentation?
Select...
Absolutely
Probably
Unsure
Unlikely
No
What will you change?
Change the medications I prescribe
Adhere more closely to ADA Standards
Prescribe finerenone more
Educate my colleagues
Educate my patients
Know better when to refer
Prescribe more SGLT-2 inhibitors
Other
If Other
Because you are likely to make changes to your practice behaviors, you are eligible to qualify for T2P (Translation to Practice) Credit, an additional 2.0 Credits. Please provide your email address below and we will send you a link to a followup survey in six weeks. If you have made changes to your practice behaviors, you will receive those additional two credits.
What barriers to change do you foresee?
Cost
Insurance Coverage
Formulary
Patient Compliance
Time with Patient
Other
If Other
What was your level of knowledge on this subject?
Before the presentation
Select...
None
Little
Some
Considerable
Expert
After the presentation
Select...
None
Little
Some
Considerable
Expert
When compared to people with T2DM without kidney disease, the presence of albuminuria and decreased eGFR increases the 10-year mortality incidence by how much?
~2-fold
~4-fold
~8-fold
~10-fold
Which of the following is true of the recommendation for use of finerenone in people with T2D and CKD by the ADA/KDIGO?
Second line in people who cannot tolerate SGLT-2 inhibitors
In people with albuminuria despite maximum tolerated dose of ACE inhibitor or ARB
Only as add-on to SGLT2 inhibitor in people with albuminuria
Only in people with albuminuria who cannot tolerate ACE inhibitor or ARB
How confident do you feel in your answer to the previous question?
Select...
Very confident
Confident
Somewhat confident
Not confident
What do you need to learn more about on this topic?
Submit